LOBE — Lobe Sciences Share Price
- CA$5.78m
- CA$7.91m
- CA$0.14m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Aug | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | 0.88 | n/a | n/a | 0.84 | 0.14 | n/a | n/a | -29.35% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaborations with partners, is engaged in research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolios. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd., and Altemia & Company, LLC.
Directors
- Jonathan Gilbert CHM (48)
- Philip Young CEO
- Brian Zasitko CFO
- Leighton Bocking IND
- Faizaan Lalani IND
- Michael Petter IND
- Last Annual
- August 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- May 13th, 2010
- Public Since
- June 19th, 2012
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Canadian Securities Exchange
- Shares in Issue
- 192,652,124

- Address
- 1400-1199 West Hastings Street, VANCOUVER, V6E 3T5
- Web
- https://www.lobesciences.com/
- Phone
- +1 6048349499
- Auditors
- Davidson & Company LLP
Upcoming Events for LOBE
Similar to LOBE
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
Asia Green Biotechnology
Canadian Securities Exchange
FAQ
As of Today at 21:48 UTC, shares in Lobe Sciences are trading at CA$0.03. This share price information is delayed by 15 minutes.
Shares in Lobe Sciences last closed at CA$0.03 and the price had moved by +100% over the past 365 days. In terms of relative price strength the Lobe Sciences share price has outperformed the Toronto Stock Exchange 300 Composite Index by +75.36% over the past year.
There is no consensus recommendation for this security.
Find out moreLobe Sciences does not currently pay a dividend.
Lobe Sciences does not currently pay a dividend.
Lobe Sciences does not currently pay a dividend.
To buy shares in Lobe Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.03, shares in Lobe Sciences had a market capitalisation of CA$5.78m.
Here are the trading details for Lobe Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: LOBE
Based on an overall assessment of its quality, value and momentum Lobe Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lobe Sciences. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +45.35%.
As of the last closing price of CA$0.03, shares in Lobe Sciences were trading +36.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lobe Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lobe Sciences' management team is headed by:
- Jonathan Gilbert - CHM
- Philip Young - CEO
- Brian Zasitko - CFO
- Leighton Bocking - IND
- Faizaan Lalani - IND
- Michael Petter - IND